CRBP — Corbus Pharmaceuticals Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595097 ·
Last close
$8.19
Market Cap
$151.74M
52W High
$12.88
52W Low
$7.12
ADV30
604,233
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,304,000 | -22,969,000 | 144,480,000 | 25,661,000 | 18,138,000 |
| Dec 2025 | 0 | — | -21,966,000 | -20,555,000 | 168,195,000 | 28,492,000 | 20,692,000 |
| Sep 2025 | 0 | — | -24,417,000 | -23,342,000 | 109,514,000 | 26,983,000 | 17,367,000 |
| Jun 2025 | 0 | — | -19,152,000 | -17,662,000 | 125,085,000 | 20,044,000 | 14,094,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,641,000
Investing CF
$2,691,000
Financing CF
$77,426,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.82
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-578,399,000
Inventory
—
Receivables
—
ST Investments
$112,558,000
EBIT TTM
$-85,863,000
Pretax Income TTM
$-84,528,000
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -85,310,000 | -78,537,000 | 168,195,000 | 20,692,000 | — | -64,491,000 |
| Dec 2024 | 0 | -48,721,000 | -40,209,000 | 155,879,000 | 13,451,000 | — | -41,794,000 |
| Dec 2023 | 0 | -45,078,000 | -44,604,000 | 28,272,000 | 35,177,000 | — | -36,100,000 |
| Dec 2022 | 0 | -34,835,445 | -42,346,903 | 66,311,940 | 33,321,923 | — | -37,544,435 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASRT | Assertio Holdings, Inc. | $151.73M | $23.48 | — |
| PRQR | ProQR Therapeutics N.V. | $151.72M | $1.44 | — |
| SLNCF | Silence Therapeutics plc | $150.21M | $1.06 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $149.22M | $1.06 | — |
| HURA | TuHURA Biosciences, Inc./NV | $147.74M | $2.32 | — |
News headlines (Yahoo Finance, 1h cache)
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
2026-06-09 09:02 · Yahoo
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
2026-06-01 14:04 · Yahoo
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
2026-05-26 11:00 · Yahoo
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
2026-05-22 07:04 · Yahoo
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
2026-05-21 12:00 · Yahoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
2026-05-14 12:00 · Yahoo
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-13 11:00 · Yahoo
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
2026-05-12 12:00 · Yahoo
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
2026-05-05 12:00 · Yahoo
Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls
2026-04-29 13:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.